Besifovir

SKU: orb1301449

Description

Besifovir is a prodrug metabolized to LB80380 and subsequently to the active antiviral LB80317. This small molecule is a potent inhibitor of hepatitis B virus replication, suitable for both in vitro enzymatic assays and in vivo preclinical studies of chronic HBV infection.

Research Area

Infectious Disease & Virology

Key Properties

• CAS Number: 441785-25-7
• MW: 299.22
• Purity: 99.42% (May vary between batches)
• Formula: C₁₀H₁₄N₅O₄P
• SMILES: C(C1(OCP(=O)(O)O)CC1)N2C=3C(N=C2)=CN=C(N)N3
• Target: HBV
• Solubility: DMSO:250 mg/mL (835.51 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (16.71 mM)

Bioactivity

• In Vivo:
  Besifovir (LB80380) is a relatively new oral acyclic nucleotide phosphonate. Areas covered: LB80380 is a prodrug of LB80331 and LB80317. It is rapidly absorbed when taken orally. Escalating doses of besifovir produce linear increase of the plasma concentration. Doses above 60mg are effective for inhibiting HBV in human. Using 60mg as an example, the maximal concentration of LB80331 in plasma is 397 ng/mL.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Besifovir, inhibit, Inhibitor, Hepatitis B virus, HBV, LB80331, LB-80331, LB 80331

Compound Identifiers

PubChem CID

5270766